Date: 2015-06-11
Type of information: Collaboration agreement
Compound:
Company: The Lead Discovery Center (LDC) (Germany) Johnson & Johnson Innovation, a J&J company (USA - NJ)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On June 11, 2015, The Lead Discovery Center GmbH (LDC) and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate innovative drug candidates for the treatment and prevention of diseases with high unmet medical needs. Over a two-year period, LDC and the team from the Johnson & Johnson’s London Innovation Centre will work together to identify on an ongoing basis translational research opportunities sourced from LDC’s top-tier academic network, including institutes from the Max Planck Society, the Helmholtz Association and various universities. Johnson & Johnson Innovation will review and evaluate the opportunities with the objective of establishing drug discovery collaborations with LDC in selected projects that are aligned with the company’s therapeutic focus areas. For each project selected by Johnson & Johnson Innovation, the partners will negotiate a collaboration agreement for its joint development at the LDC up to the next mutually agreed milestone. The details regarding financial provisions and research activities will be agreed on a project-by-project basis to ensure a fair balance of investments and potential returns between the partners. Any revenue received from commercialization will be shared with the academic inventors and collaborating institutions.
Financial terms:
Latest news:
